Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Anavex Life Sciences Corp AVXL

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.


NDAQ:AVXL - Post by User

Post by R_J_on Jan 02, 2020 4:15am
172 Views
Post# 30510099

End of Year; End of Month; 2019, December

End of Year; End of Month; 2019, DecemberEnd of the Year Report for 2019
-
AVXL  closed on 12/31/2019 at US$2.59
AVXL  closed on 12/31/2018 at US$1.56
-
This is a GAIN of 66.0%, or US$1.30, for the year 2019.
-
AVLX's 2019 Price Range: US$4.09 - US$1.48

*****************************************************************
End of the Month (EOM) report for December 2019 FOR Anavex Life Sciences Corp.

-
AVXL closed on 12/31/2019 at US$2.59
AVXL closed on 11/29/2019 at US$2.40
-
This is a 7.9%, a 19-cent, GAIN for December.
-
S&P 500 Index, @ 3,230.7 gained 2.9% in December. [8.9% above its MA(200) @ 2,997.8]
The S&P 500 started the year 2019 @ 2506.8, it ended the year up 28.9%, or 723.9.
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's  MA(200) ended December at $2.88
AVXL is now 10.1% below its MA(200).
-
News Releases on the AVXL Website in December
-
Use this link to see and read the all of December’s News Releases.
-
https://www.anavex.com/2019/12/
-
https://www.anavex.com/2019/12/
-
Who is the Big Cheese at AVXL?
Christopher U. Missling, PhD, President & CEO
-
-
To my noble brother shareholders:
May the New Year, 2020, be prosperous for you,
May you stay healthy.

-
RJ


<< Previous
Bullboard Posts
Next >>